StockNews.AI
ETON
StockNews.AI
168 days

Eton Pharmaceuticals to Host Virtual Investor Day and Release Fourth Quarter Earnings Results on March 18, 2025

1. Eton plans a virtual Investor Day on March 18, 2025. 2. The event will cover Q4 2024 financial results and future strategy. 3. Eton highlights its product portfolio for rare diseases and market outlook. 4. Recent acquisitions include Increlex® and Galzin® for rare diseases. 5. CEO and other executives will discuss company strategy and market opportunities.

Earnings
-0.13%Current Return
VS
-0.7%S&P 500
$15.0303/04 06:56 AM EDTEvent Start
$15.0103/05 01:16 PM EDTLatest Updated
6m saved
Insight
Article

FAQ

Why Bullish?

The upcoming Investor Day indicates positive momentum and growing investor interest, similar to previous successful events that led to stock price increases due to enhanced visibility for Eton's portfolio and strategic direction.

How important is it?

The article presents significant company developments and strategic direction that are likely to affect investor sentiment and stock performance in the near term.

Why Short Term?

Immediate investor interest may drive price action leading up to and following the March 18 event, as seen in past announcements that created short-term spikes in stock performance.

Related Companies

ETON
March 04, 2025 06:50 ET  | Source: Eton Pharmaceuticals DEER PARK, Ill., March 04, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will hold a virtual Investor Day and report fourth quarter 2024 financial results on Tuesday, March 18, 2025, beginning at 10:00 a.m. ET (9:00 a.m. CT). In addition to discussing fourth quarter 2024 financial results, the Investor Day event will offer investors an in-depth look at Eton’s rare disease portfolio and financial outlook after a transformational six months. The company will share its view of the long-term market opportunity and commercial strategy for the recently acquired Increlex® and Galzin® products, as well as provide an update on its adrenal insufficiency franchise, Alkindi Sprinkle® and ET-400, and the associated market landscape. In addition, the company will highlight recent developments within its pipeline of attractive rare disease product candidates. Featured speakers include Sean Brynjelsen, Chief Executive Officer, James Gruber, Chief Financial Officer, David Krempa, Chief Business Officer, and Ipek Erdogan-Trinkaus, Chief Commercial Officer. Audience members will have the opportunity to ask questions following the prepared remarks. To participate, please click here to register. An archived webcast will be available on the Investors section of Eton’s website approximately two hours after the completion of the event and for 30 days thereafter. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has four additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc.

Related News